What Is Orforglipron? Inside a CU Anschutz Clinical Trial for a New Oral GLP-1 Weight Loss Drug
Carie Behounek
The takeaway:
Orforglipron is an FDA-approved non-peptide oral GLP-1 pill, offering a potential alternative to injectable weight-loss drugs. Demand for GLP-1 medications has surged in recent years, but cost and injectable delivery have limited access for many patients. A CU Anschutz researcher is overseeing a clinical trial for orforglipron, and a patient shares her experience in the trial.
Every morning for two years, Julia Swaney has popped a pill, hoping it would quiet the “food noise” she’s.